This content is from: Home

Big pharma looks to generics and biotech for growth

There have been nearly $70 billion worth of deals in the pharmaceutical industry in 2008, almost double the value of last year. Eklavya Gupte investigates the reasons why there is so much activity and finds out how IP is driving the deals

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | One Week Trial